Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

SRR8613712

— · D

906d57ab-2739-577c-b1f6-08c7c666a0ee

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
D
subtype
D

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • INTERFERON_ALPHA_RESPONSE+0.750
  • INTERFERON_GAMMA_RESPONSE+0.670
  • ALLOGRAFT_REJECTION+0.570
  • IL6_JAK_STAT3_SIGNALING+0.440
  • COMPLEMENT+0.420
  • IL2_STAT5_SIGNALING+0.350
  • INFLAMMATORY_RESPONSE+0.350
  • PI3K_AKT_MTOR_SIGNALING+0.260
  • KRAS_SIGNALING_UP+0.210
  • UV_RESPONSE_DN+0.180

Top 10 suppressed

  • GLYCOLYSIS-0.390
  • ADIPOGENESIS-0.290
  • ESTROGEN_RESPONSE_EARLY-0.290
  • HYPOXIA-0.280
  • MYC_TARGETS_V2-0.260
  • OXIDATIVE_PHOSPHORYLATION-0.250
  • APICAL_SURFACE-0.240
  • ESTROGEN_RESPONSE_LATE-0.200
  • FATTY_ACID_METABOLISM-0.200
  • SPERMATOGENESIS-0.190

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR8518387
breast-umap@18
—D0.849
2SRR8518228
breast-umap@18
—D0.849
3SRR8518123
breast-umap@18
—D0.846
4BSR_02_0049_A5_S69
breast-umap@18
—D0.844
5TCGA-AR-A1AW-01A-21R-A12P-07
breast-umap@18
—D0.839
6SRR8613774
breast-umap@18
—D0.836
7SRR8518332
breast-umap@18
—D0.833
8SRR8613787
breast-umap@18
—D0.824
9SRR8518235
breast-umap@18
—D0.823
10SRR8518454
breast-umap@18
—D0.821

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 22 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
INTERFERON_ALPHA_RESPONSE0.750Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.670Idelalisib— uncovered
ALLOGRAFT_REJECTION0.570Idelalisib— uncovered
IL6_JAK_STAT3_SIGNALING0.440Inavolisib— uncovered
COMPLEMENT0.420Inavolisib— uncovered
IL2_STAT5_SIGNALING0.350Idelalisib— uncovered
INFLAMMATORY_RESPONSE0.350Idelalisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.260Inavolisib— uncovered
KRAS_SIGNALING_UP0.210Inavolisib— uncovered
UV_RESPONSE_DN0.180Inavolisib— uncovered
APOPTOSIS0.170Idelalisib— uncovered
G2M_CHECKPOINT0.120Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.090Inavolisib— uncovered
UV_RESPONSE_UP0.080Idelalisib— uncovered
ANDROGEN_RESPONSE0.060Inavolisib— uncovered
COAGULATION0.060Binimetinib— uncovered
DNA_REPAIR0.050Idelalisib— uncovered
ANGIOGENESIS0.040Remibrutinib— uncovered
PANCREAS_BETA_CELLS0.040Cobimetinib— uncovered
APICAL_JUNCTION0.010Inavolisib— uncovered